Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

A composition containing a polymer material and a phosphorus-containing flame retardant based on an amino methyl bisphosphonate, a process for the production of the composition, and the use of the flame retardant as well as selected structures of the flame retardant are disclosed.

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

Disclosed is an oleic acid derivative including a hydrophobic part C17H33 linked to a particular polar head part “A”, especially for use as a medicament, for instance, for the treatment of a disorder caused by the GPR120 receptor and/or the CD36 receptor, including administering to a subject in need thereof a therapeutically effective amount of the oleic acid derivative or of the pharmaceutical composition. Also disclosed is the use of the oleic acid derivative as a food composition.

Compounds represented by Formula (I) and (II) and salts thereof are described herein. The compounds or salts of Formula (I) and (II) may be used to treat senescence-associated diseases and disorders. ##STR00001##

The present invention relates to novel phosphonoamidate prodrugs. The invention also relates to the use of these novel phosphonate-modified nucleosides to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with viruses such as the herpes simplex virus 1, herpes simplex virus 2, human cytomegalovirus, varicella zoster virus, vaccinia virus and adenovirus.

Disclosed are novel phosphono-phosphate compounds, monomers, and polymer compositions that have targeted uses with divalent cations and surfaces having divalent cations. These compounds can be used to deliver actives to surfaces such as calcium hydroxyapatite.

Disclosed are novel phosphono-phosphate polymer compositions with multi-valent cations in aqueous solutions. These compositions can further include mono or multivalent anions.

A method for preparing the cyclic phosphonate compound of Formula I

##STR00001##

is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Provided are a compound for treating metabolic diseases having the structure as shown in formula (I) or formula (II), or a racemate, stereoisomer, geometric isomer, tautomer, solvate, hydrate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The compound is an activator of FXR and/or a TGR5 receptor, and thus has the activity of activating FXR and/or a TGR5 receptor, and can be used in the preparation of drugs for treating chronic liver diseases, metabolic diseases or portal hypertension.